composite cultured skin

composite cultured skin

Dermatology A skin substitute used to cover burn wounds and epidermolysis bullosa. See Artificial skin.
Mentioned in ?
References in periodicals archive ?
NASDAQ: ORTC) announced today that it has received permission from the Food and Drug Administration (FDA) to commence a pivotal (final stage) clinical trial using a cryopreserved (frozen) version of its Composite Cultured Skin (CCS) product to treat venous statis skin ulcers, a commercial market in the United States estimated to be in excess of $1 billion.
Ortec's Chairman and CEO, stated that "Ortec is still in the development stage and its financial operations in 2000 were consistent with management's projections as to use of cash needed for the development and clinical trials of the Company's Composite Cultured Skin (CCS) for the treatment of skin wounds resulting from venous and diabetic ulcers, donor sites and epidermolysis bullosa.
NASDAQ: ORTC) announced today that it will file four additional patents with the United States patent office further enhancing and broadening the proprietary aspects of its Composite Cultured Skin (CCS) technology.
NASDAQ: ORTC) today announced that the clinical data from its recently concluded pivotal (final stage) clinical trial evaluating the use of its Composite Cultured Skin (CCS) for facilitating wound closure of split thickness skin donor site wounds in burn patients achieved statistical significance for its primary endpoint, time to 100% wound closure.
Andrew Salzberg of Westchester County Medical Center Burn Unit presented long-term follow-up data on seven patients with severe burns treated with Ortec International's (Nasdaq: ORTC) Composite Cultured Skin (CCS) at the 29th Annual Meeting of the American Burn Association in New York City.
Nasdaq:ORTC) announced today that the Food and Drug Administration (FDA) has accepted the company's filing of a Pre-Market Approval (PMA) application for its Composite Cultured Skin (CCS) tissue-engineered product submitted to the FDA on March 5, 2001.
Kodiyalam will be directly responsible for planning and implementing the marketing and distribution initiatives for commercialization of Ortec's Composite Cultured Skin (CCS) product.
of New York is a publicly traded (Nasdaq: ORTC) company that has developed and patented a product called Composite Cultured Skin, which is used to stimulate the repair and regeneration of human skin, particularly in burn victims.
Composite cultured skin (CCS) is composed of human skin cells, which are derived from infant foreskin and placed on a porous collagen scaffold.
Nasdaq: ORTC) announced today that it received approval from the Food & Drug Administration (FDA) to market its Composite Cultured Skin (CCS) product for use in patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) undergoing hand reconstruction, as well as to cover donor sites (the area from where skin was removed from another part of the patient's body) created during the surgery.
Ortec International is a development stage biomaterial and cell culture biotechnology company that has developed a patented technology, Composite Cultured Skin (CCS), that acts as a biologically active dressing that stimulates the repair, replacement and regeneration of human skin.